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Abstract
Background: To correlate parameters of Ultrasonography-guided Diffuse optical tomography (US-DOT) with
pharmacokinetic features of Dynamic contrast-enhanced (DCE)-MRI and pathologic markers of breast cancer.
Methods: Our institutional review board approved this retrospective study and waived the requirement for informed
consent. Thirty seven breast cancer patients received US-DOT and DCE-MRI with less than two weeks in between
imaging sessions. The maximal total hemoglobin concentration (THC) measured by US-DOT was correlated with
DCE-MRI pharmacokinetic parameters, which included Ktrans, kep and signal enhancement ratio (SER). These
imaging parameters were also correlated with the pathologic biomarkers of breast cancer.
Results: The parameters THC and SER showed marginal positive correlation (r = 0.303, p = 0.058). Tumors with
high histological grade, negative ER, and higher Ki-67 expression ≥20 % showed statistically higher THC values
compared to their counterparts (p = 0.019, 0.041, and 0.023 respectively). Triple-negative (TN) breast cancers
showed statistically higher Ktrans values than non-TN cancers (p = 0.048).
Conclusion: THC obtained from US-DOT and Ktrans obtained from DCE-MRI were associated with biomarkers
indicative of a higher aggressiveness in breast cancer. Although US-DOT and DCE-MRI both measured the
vascular properties of breast cancer, parameters from the two imaging modalities showed a weak association
presumably due to their different contrast mechanisms and depth sensitivities.
Background
Mammography is a sensitive imaging method for detec-
tion of breast cancers [1] and that has contributed to the
improvement of the survival rates for breast cancer [2].
However, the sensitivity of mammography drops down to
62 % in cases of dense breasts [3]. Complementary im-
aging methods have been introduced to identify mammo-
graphically occult breast cancers, as well as to differentiate
malignant lesions from benign lesions based on the mor-
phologic and physiologic characteristics of breast lesions
[4–14]. Ultrasonography (US) is the most commonly used
supplemental imaging method to improve the sensitivity
of breast cancer detection; however, it is also known to
yield a high number of false positives [4, 6, 12]. Several
additional techniques, including elastography, Doppler,
and optical imaging, have been introduced to improve
the specificity of US through leveraging functional pa-
rameters that complement the traditional morpho-
logical parameters [7, 10, 15].
Diffuse optical tomography (DOT) is a suitable breast
imaging modality that measures functional characteris-
tics of breast lesions, by using near infrared light to
probe tissue optical properties. The parameters that can
be measured include the concentrations of water, lipid,
as well as oxy-hemoglobin and deoxy-hemoglobin that
can be used to calculate the total hemoglobin concentra-
tion and the oxygen saturation. Hemoglobin concentra-
tion is known to be related to angiogenesis, which is
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critical for autonomous growth and the spread of breast
cancer [16, 17]. However, the low spatial resolution of
DOT has limited its clinical application [18]. Recently, the
availability of ultrasonography-guided diffuse optical tom-
ography (US-DOT) has increased its usefulness as a com-
plementary imaging modality for breast imaging, with the
technique combining both morphologic characteristics
found with US and functional information found with
DOT [15, 19, 20]. In a previous report on patients with
breast cancer, the total hemoglobin measured by US-DOT
was correlated with tumor size and several molecular bio-
markers (HER2 and Ki-67), and it was shown to have po-
tential for predicting tumor aggressiveness [21].
Another approach to measure angiogenic properties of
breast tissue is dynamic contrast-enhanced MRI (DCE-
MRI), an important clinical imaging modality for detection
and diagnosis of breast cancer. In addition to providing
high quality breast images not limited by dense breasts, it
can also be used to access vascular information by using a
dynamic imaging protocol. Pharmacokinetic parameters
such as Ktrans and kep are commonly used to characterize
neovascularization in breast cancer. These kinetic parame-
ters are also reported to correlate with biomarkers and can
be used to predict poor prognosis [22]. Therefore, both
US-DOT and DCE-MRI can be applied to measure tumor
angiogenesis, and are known to yield quantitative parame-
ters for characterizing angiogenic properties of tumors.
However, there have been few studies that compare
US-DOT and DCE-MRI to evaluate their correlation.
The purpose of this study was to investigate the cor-
relation of parameters measured by US-DOT with phar-
macokinetic features measured by DCE-MRI to evaluate
breast tumor angiogenesis, as well as to investigate the
association of these imaging parameters with pathologic
and molecular biomarkers of breast cancer.
Methods
This study was approved by the Severance Hospital In-
stitutional Review Board, and the requirement for in-
formed consent was waived for this retrospective study.
Patients gave informed consent prospectively prior to
US-DOT when they were diagnosed with breast cancer,
and the written informed consent included consent for
the future use of their US-DOT information in the com-
prehensive research of breast disease.
Study population
Among 63 consecutive pathologically-proven breast can-
cer patients who underwent US-DOT between June 2009
and August 2009 in our institution, 37 patients with breast
cancer underwent diagnostic breast DCE-MRI within
2 weeks of US-DOT imaging. All of these patients under-
went surgery at our institution and were included in the
analysis for this study. Because core-biopsy can affect the
value of US-DOT parameters, US-DOT imaging was done
before the core-biopsy for all cases in our study.
US-localized diffuse optical tomography
The US-DOT was done using a commercially available
breast diagnostic equipment, OPTIMUS type II (Xinao-
MDT Technology Co., Ltd, China). It is a dual imaging
modality combining conventional ultrasound (Terason
T3000 ultrasound, Teratech, USA) and near-infrared
(NIR) optical tomography, which can be used to measure
functional tissue properties with optical spectroscopic
analysis. The main functional parameter is the oxy- and
deoxy-hemoglobin concentration calculated from absorp-
tion coefficients measured by using two optical wave-
lengths (785 nm and 830 nm). The optical probe delivered
light with an array of nine optical fibers and detected
reflected light through the tissue with an array of ten op-
tical guides [23]. The technical details of this imaging sys-
tem, including system configurations, imaging acquisition
methods, and the data processing algorithms, have been
described in a previous report [15]. The US-DOT system
can detect up to 35 mm into the tissue. The system recon-
structs 7 slices from the skin, each with 5 mm thickness.
For the thirty seven patients in our study, the mean size of
breast lesions was 18.4 mm. We carefully positioned the
breast of each subject to ensure that US-DOT could cover
the entire lesion. The mean thickness of the breast, de-
fined as the distance between the skin surface to the chest
wall muscle, was 20.9 mm on US image. With the excep-
tion of 2 cases, the breast thickness was smaller than
25 mm. After conventional US evaluation, the US-DOT
imaging procedure was done using the hybrid handheld
probe through following the manufacturer’s recom-
mended protocol. Briefly, the lesion was identified by a
linear 7–12 MHz ultrasound transducer in the center
of the hybrid probe to find the maximal diameter of
the lesion.
Based on the US images, a square region of interest
(ROI) was drawn to include the maximal diameter and
the perpendicular dimension of the lesion. Since the
ROI was a square shape, it encompassed the whole area
of the identified lesion and a small portion of the sur-
rounding normal tissues. Then the optical imaging was
acquired using the same hybrid probe. The plane that
showed the maximal diameter of the tumor was used as
the optical horizontal plane. Then, the probe was rotated
by 90° angle to acquire the optical data from the vertical
plane. Next, we performed the same process in the sym-
metric region in the contralateral normal breast, including
the horizontal and vertical planes. The optical imaging
measured the normal site in the symmetrical region of the
contralateral breast was used as references in the recon-
struction. After scanning the four planes (two lesion
planes and two contralateral normal planes), the optical
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characteristic parameters and the total hemoglobin con-
centration (THC, micromoles per liter) were obtained by
calculating the difference between the lesion and the sym-
metric normal site, and the images were displayed on the
screen of the imaging system. The maximal THC value
was determined as the maximal hemoglobin concentra-
tion in the region of interest box (Fig. 1a , b).
DCE-MRI study protocol
Breast MR imaging was performed with a patient in the
prone position using a 1.5 T MR scanner (Philips Health-
care, Best, Netherlands) with a dedicated bilateral breast
coil. The DCE-MRI sequence was based on a 3D gradient
echo sequence (repetition time/echo time, 7.0/3.4 ms; flip
angle, 12°; bandwidth 215 Hz/pixel; slice thickness, 3 mm;
FOV, 340 mm × 340 mm; matrix size, 368 × 302; voxel
size, 0.7 × 0.7 × 3.0 mm) with axial sections. A total of 7
dynamic frames (repetitions) were acquired. Each frame
took 66 s resulting in a total imaging time of approximately
7 min and 42 s. Gadolinium diethylene triaminepenta
acetic acid (Gd-DTPA, Magnevist; Berlex Laboratories,
Inc., Montville, NJ, USA; 0.2 cc/kg) was injected manually
at the start of the second-frame acquisition, and then
followed by a 10-cc saline flush. The total injection time of
the contrast agent was maintained between 15 and 20 s for
every patient to make the bolus length as consistent as pos-
sible. The saline flush was given as a fast bolus. All MR im-
ages were transferred from the MR-console to a personal
computer for post-processing.
DCE-MRI kinetic parameters
The analysis of DCE-MRI enhancement kinetics was
done by a radiologist with 8 years of experience in breast
imaging interpretation. The tumor was determined from
the color-coded enhancement maps which were gener-
ated by subtracting the pre-contrast images from the
first post-contrast images. On each imaging slice show-
ing the enhanced tumor, a ROI was manually drawn to
outline the entire tumor (e.g. Fig. 1c). The signal inten-
sity time course was calculated from each ROI, and the
calculated time courses from all the tumor ROIs drawn
on different imaging slices were averaged to calculate a
mean signal intensity time course for this study. Signal
intensities measured from seven post-contrast frames
were normalized by the signal intensity measured from
the pre-contrast images. The enhancement kinetics was
then analyzed by using the Tofts two-compartmental
pharmacokinetic model [24]. The pharmacokinetic pa-
rameters, Ktrans, and kep, represented the uptake rate and
washout rate of the Gadolinium contrast agent, respect-
ively. A Matlab program (version 6.0.0.88; The Math-
Works, Inc., USA) was written to fit the measured
enhancement time course to the time course generated
by the two-compartmental model, and the parameters
Ktrans, and kep were obtained after the fitting. The signal
enhancement ratio (SER) was related to the washout
slope in DCE kinetics and calculated as: SER = (S1-S0)/
(S2-S0), where S0 is the pre-contrast signal intensity, S1
is the peak signal intensity approximately at 90 s post in-
jection, and S2 is the signal intensity at the last time
point in the DCE sequence.
Pathologic parameters
Histopathological results and molecular biomarkers, in-
cluding tumor size, histologic grade (HG), estrogen re-
ceptor (ER), progesterone receptor (PR), HER-2, Ki-67,
Fig. 1 A woman with invasive ductal carcinoma (a) A gray-scale ultrasound image shows a hypoechoic mass with microlobulated margins, measuring
1.8 cm in diameter (high histologic grade, LVI (−), ER(−), PR(−), HER-2 (+), Ki-67 (+)). b A reconstructed optical absorption map shows a distinct mass
with a high maximum THC of 293.4 μmol/L. The first section (slice 1, top left) is a 6 × 6 cm spatial x-y image (coronal plane of the body) obtained at a
depth of 0.5 cm, as measured from the skin surface. The last section (slice 7, bottom left) is a 6 × 6 cm spatial x-y image (coronal plane of the body)
obtained at a depth of 3.5 cm, as measured from the skin surface. Spacing between sections is 0.5 cm in the direction of propagation. c A lobular
homogenously enhancing mass is noted from one of the DCE-MRI slices. The Ktrans is 0.122 [1/min], the kep is 0.415 [1/min] and the SER is 1.024
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lymphovascular invasion and axillary lymph node metas-
tasis (LN mets), were evaluated for each case from surgi-
cal specimen. Histologic grade was determined with
evaluation of mitosis, tubular formation and nuclear
grade, all correlated with cellularity. The status of ER,
PR, HER-2 and Ki-67 were determined based on patho-
logic results with immunohistochemical assays. Tumors
with ≥ 1 % nuclear-stained cells were considered positive
for ER and PR according to the American Society of
Clinical Oncology/College of American Pathologists
(ASCO/CAP) guidelines. HER-2 was considered positive
for 3 +, or 2+ with amplification on the FISH test.
Triple-negative breast cancer (TNBC) was defined as
breast cancers showing negative ER, PR, and HER-2. Ki-
67 staining was assessed with the percentage of nuclei
showing a positive reaction. An arbitrary cut-off point
of ≥ 20 % was used to define high Ki-67 expression,
while the value less than 20 % was low. The tumor size
was determined as the maximal diameter of the invasive
component at surgical pathology. The presence of axil-
lary lymph node was determined with surgical patho-
logic reports; and the presence of systemic metastasis
was determined with medical records.
The more aggressive tumor was defined by larger
tumor size, high histologic grade, negative ER, TNBC,
high Ki-67 expression, positive lymphovascular invasion,
and the presence of positive axillary lymph node metas-
tasis and systemic metastasis.
Statistical analysis
Pearson correlation was employed to determine whether
the THC and DCE-MRI kinetic parameters (Ktrans, kep
and SER) were correlated with each other. In Pearson’s
correlation, a coefficient |r| < 0.2 indicates a correlation
that is very weak, 0.2 ≤ |r| < 0.4 weak, 0.4 ≤ |r| ≤ 0.6 mod-
erate, 0.6 ≤ |r| < 0.8 strong, and |r| ≥ 0.8 very strong [25].
The lesions were separated into two dichotomized
groups based on each pathologic biomarker, and the dif-
ference between the values of imaging parameters in the
two groups was compared using the student t-test. Stat-
istical analysis was performed using the SPSS statistical
analysis software (IBM SPSS Statistics, version 20.0.0;
SPSS, Chicago, Ill), with the significance level set at a
two-sided p value of < 0.05.
Results
All 37 patients underwent surgery, and Table 1 shows
the pathologic findings.
The correlation between US-DOT parameter and DCE-MRI
parameters
Between the THC and DCE-MRI parameters, only THC
and SER showed a weak correlation with statistically
marginal significance (r = 0.303, p = 0.058, Table 2). A
higher total hemoglobin concentration was correlated with
a more rapid washout rate (Fig. 1). There was no statistical
significance in the correlation of THC and other two
DCE-MRI parameters (r = −0.237 with Ktrans, p = 0.157;
r = −0.218 with kep, p = 0.195). Fig. 2 illustrates one ex-
ample of discordant findings between DCE-MRI and
THC; while an unenhanced necrotic core is clearly
noted on MRI, a high homogeneous THC map is
shown on US-DOT. The mean and standard deviation
value for each parameter are shown in Table 3.
Table 1 Clinicopathologic biomarkers of the 37 breast cancer
patients
Pathologic biomarkers Number
Menstrual status Premenopause 16
menopause 21
Histology Invasive ductal carcinoma 31
Invasive lobular carcinoma 1
Invasive micropapillary carcinoma 3
Poorly differentiated carcinoma 2
Tumor size <2 cm 20
≥2 cm 17
Histologic grade Low 16
High 21
Estrogen receptor Negative 15
Positive 22
Progesterone receptor Negative 13
Positive 24
HER-2 Negative 31
Positive 6
Triple-negative Negative 27
Positive 10
Ki-67 Low 18
High 19
Lymphovascular invasion Negative 23
Positive 3
Not available 11
Lymph node metastasis Negative 24
Positive 13
Table 2 The correlation between US-DOT parameters and
DCE-MRI kinetics in the 37 breast cancers
Pearson Correlation THC P
Ktrans -.237 .157
kep -.218 .195
SER .303 .058
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The correlation between US-DOT parameter and pathologic
parameters
High histologic grade, ER-negativity, and higher Ki-67
expression ≥20 % showed a higher THC value with stat-
istical significance (p = 0.019, 0.041, and 0.030, respect-
ively) compared to their counterparts (Table 4). Since
cancers with high-grade, negative ER and high Ki-67
were considered as more aggressive, THC was associated
with aggressiveness.
The correlation between DCE-MRI parameters and
pathologic parameters
For DCE pharmacokinetic parameters, triple-negative (TN)
breast cancers showed a higher Ktrans than non-TN tumors
(p = 0.048). Cases with negative HER-2 had higher Ktrans
values than those with positive HER-2; and cases with high
Ki-67 ≥ 20 % had higher Ktrans than those with Ki-67 <
20 %, with marginally statistical significances (p = 0.051 and
0.060, respectively, Table 5). There was no significant differ-
ence in kep between tumors with different pathologic pa-
rameters or molecular biomarkers.
Discussion
As tumors cannot grow beyond 2 mm simply with nutri-
ents supplied through diffusion, angiogenesis becomes a
critical process for sustained tumor growth. Angiogenesis
is capable of differentiating between malignant and benign
tumors and can be used as a discriminating characteristic
of aggressiveness [16]. The wall of neovascularity tends to
be leaky, and the increased permeability results in early
and rapid contrast-enhancement on MRI. Pharmacoki-
netic parameters are very useful in the characterization of
angiogenesis in breast cancer and have been shown to be
associated with the spread of breast cancer and patient
prognosis.
Fig. 2 A woman with invasive ductal carcinoma (a) A gray-scale ultrasound image shows an isoechoic mass with central markedly hypoechoic
component (arrow), which can present central necrosis (high histologic grade, LVI (−), ER(−), PR(−), HER-2 (−), Ki-67 (+)). b A reconstructed optical
absorption map shows a distinct mass with a high maximum THC of 377.3 μmol/L with central prominent high signal. c dynamic contrast-en-
hanced MRI shows a round mass with rim enhancement with central non-enhancing area, correlated with central hypoechogenicity on US (a)
and high signal intensity (arrow) on T2 weighted image (d). The Ktrans is 0.132 [1/min], the kep is 0.521 [1/min] and the SER is 1.002. The surgical
specimen shows central necrosis
Table 3 The mean and standard deviation of US-DOT and DCE-
MRI parameters in the 37 breast cancers
Mean ± Stdev
US-DOT THC 181.296 ± 76.888
DCE-MR Ktrans 0.133 ± 0.066
kep 0.482 ± 0.157
SER 1.057 ± 0.063
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The THC measured by DOT represents blood volume,
which has been reported to have high values in malig-
nant tumors [15, 20, 26]. Therefore, high THC measured
by DOT is generally associated with tumors showing
contrast-enhancement identified by MRI [27–30]. Sev-
eral MR-compatible DOT systems have been developed
for breast imaging, which has the advantage of improv-
ing the quality of reconstructed DOT images by using
the morphological information provided by DCE-MRI as
a priori information [28–33]. Since tumors were co-
registered, the obtained information by DCE-MRI and
DOT could be easily compared. The suspicious malig-
nant lesions on DCE-MRI were reported to show higher
mean absorption coefficient than benign lesions [32].
DCE-MRI is an established clinical imaging modality
for breast cancer. For research, pharmacokinetic analysis
is commonly applied to obtain parameters. Ktrans is the
inflow transfer constant, which is related to the delivery
of contrast agent to the tumor through vascular perfu-
sion and permeability, while kep is the out-flux transfer
rate constant for the contrast agent to diffuse from the
extracelluar extravascular space back to the plasma com-
partment [26]. The signal enhancement ratio measures
the washout slope based on signal intensities at three
time points, which is also related to perfusion and
permeability [34]. These DCE-MRI parameters as well as
the THC measured by DOT have been correlated with
the histologic microvascular density count [35].
The mean THC results could be affected by tumor het-
erogeneity and the partial volume effect (i.e. inclusion of
normal issues in the measurement) [36]; therefore, in this
study we chose to analyze the maximal THC, which was
measured as the maximum THC value within the tumor
ROI box. A suggested cutoff value of THC for malignancy
was 140 μmol/L in a previous report [20], but it was also
reported that many malignant tumors could have a lower
THC value around 100 μmol/L [36]. In our results, the
mean value of the THC was 181.3 μmol/L, comparable
with results in the previous report [20]. In the correlation
analysis between US-DOT parameters and clinicopatho-
logic characteristics, several poor prognostic biomarkers,
including high histologic grade, ER negativity and high Ki-
67 expression, were significantly correlated with a high
THC. Histologic grade is one of three strongest prognostic
determinants, which include LN mets, tumor size and
histologic grade [37]. Ki-67 is a marker of cell proliferation
including the S-phase fraction, mitotic index and bromo-
deoxyuridine uptake [38]. High Ki-67 expression has been
regarded as a characteristic of more aggressive prolifera-
tion as well as neovascularization; it is also associated with
Table 4 Total hemoglobin concentration of US-DOT according
to pathologic biomarkers
Total hemoglobin concentration (μmol/L)
Mean p
Tumor size <2 cm (n = 20) 172.15 0.440
≥2 cm (n = 17) 192.06
HG Low (n = 16) 147.98 0.019
High (n = 21) 206.68
ER Neg (n = 15) 212.27 0.041
Pos (n = 22) 160.02
PR Neg (n = 13) 211.86 0.075
Pos (n = 24) 164.73
HER-2 Neg (n = 31) 179.63 0.769
Pos (n = 6) 189.91
TNBC Neg (n = 27) 173.12 0.294
Pos (n = 10) 203.38
Ki-67 Low (n = 18) 153.52 0.030
High (n = 19) 207.61
LVI Neg (n = 23) 175.45 0.581
Pos (n = 3) 146.14
LN mets Neg (n = 24) 179.84 0.879
Pos (n = 13) 183.97
mets Neg (n = 36) 180.36 0.663
Pos (n = 1) 214.97
Table 5 Parameters of DCE-MRI according to pathologic
biomarkers
Ktrans kep SER
(1/min) (1/min)
Mean p Mean p Mean p
Overall
Tumor size <2 cm (n = 20) 0.134 0.885 0.495 0.440 1.118 0.471
≥2 cm (n = 17) 0.131 0.468 1.085
HG Low (n = 16) 0.136 0.829 0.484 0.965 1.136 0.199
High (n = 21) 0.131 0.481 1.077
ER Neg (n = 15) 0.156 0.124 0.513 0.337 1.111 0.746
Pos (n = 22) 0.118 0.462 1.096
PR Neg (n = 13) 0.154 0.162 0.485 0.932 1.119 0.613
Pos (n = 24) 0.122 0.481 1.091
HER-2 Neg (n = 31) 0.138 0.051 0.487 0.684 1.109 0.526
Pos (n = 6) 0.107 0.458 1.069
TNBC Neg (n = 27) 0.116 0.048 0.482 0.985 1.103 0.996
Pos (n = 10) 0.178 0.483 1.103
Ki-67 Low (n = 18) 0.113 0.060 0.470 0.629 1.103 0.989
High (n = 19) 0.154 0.495 1.102
LVI Neg (n = 23) 0.135 0.514 0.504 0.818 1.115 0.726
Pos (n = 3) 0.113 0.478 1.082
LN mets Neg (n = 24) 0.123 0.206 0.498 0.412 1.112 0.581
Pos (n = 13) 0.152 0.453 1.085
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a good chance of clinical response to chemotherapy
[39, 40]. In this study, the THC in high Ki-67 ≥ 20 %
cancers (mean ± SD, 207.61 ± 80.15 μmol/L) was higher
than in low Ki-67 < 20 % cancers (mean ± SD, 153.52 ±
64.07 μmol/L). With our results, it could be suggested
that breast cancers showing a high THC have poorer
prognosis than those with a low THC. There was no
difference between THC values in HER-2 positive and
HER-2 negative groups (p > 0.05), different from Brown
et al. [41] and Choi et al. [21]. In our study population,
only 6 cancers were HER-2 positive while 31 were
HER-2 negative. The low rate of HER-2 positive cancers
was possibly from case selection bias (because both US-
DOT and DCE-MRI scans were required), and the insuffi-
cient case number might affect the results. We also found
a higher THC value in larger tumors (≥2 cm) than in
smaller ones (<2 cm), but the difference was not statisti-
cally significant.
As the use of breast US-DOT in current clinical prac-
tice increases [15, 19, 21, 35, 36], there has been efforts
to assess the correlation of THC with parameters mea-
sured by other imaging modalities [42, 43]. Zhu et al.
compared US-DOT with the color Doppler flow imaging
and found that the THC value did not differ significantly
in malignancies with or without vascular tissue shown
on Doppler flow imaging. Doppler flow imaging is based
on detection of blood flow motion with relatively high
velocity in large vessels, while optical imaging is mainly
sensitive to the capillary blood volume within the tumor,
which might explain the disagreement [43]. Similarly, in
our study we did not find a high correlation between MR
parameters and US-DOT results, presumably because of
the different imaging principles on which the two tech-
niques are based, as well as the analysis methods. Since a
low molecular weight contrast agent (Gd-DTPA) is used
for DCE-MRI, the agent can easily leak from the plasma
compartment to the extravascular-extracellular compart-
ment, and it is well known that the DCE kinetics are heav-
ily dependent on the vascular permeability and the
distribution volume in the extravascular-extracellular space
[22, 26]. For example, DCE-MRI can miss breast cancers
showing low angiogenesis such as in low-grade DCIS [44].
In contrast, the THC measured by optical imaging is
mainly related to the total blood volume without
involvement of vascular permeability or distribution
space, therefore the fundamental differences in the con-
trast mechanism could explain the lack of a high correl-
ation between DCE-MRI and US-DOT parameters.
Understanding the tumor microenvironment for angio-
genesis can be complicated, and results obtained using dif-
ferent methods may not be well correlated. For example,
although US-DOT, Color Doppler flow imaging, and
DCE-MRI are all based vascular properties for measure-
ments, Color Doppler imaging shows no significant
correlation with microvessel counts [45], while some
DCE-MRI parameters were reported to be correlated with
microvessel density but not specifically with VEGF, a po-
tent factor to stimulate angiogenesis [46]. Another major
reason leading to the poor correlation of parameters is the
high heterogeneous nature of the tumor. In this study, for
DCE-MRI we included all enhanced tumor tissues from
multiple imaging slices as ROI to evaluate kinetics on MR
imaging, therefore, it is more like a “whole tumor analysis”
approach. In US-DOT the maximum THC value in the
ROI box was obtained and used for analysis, thus it is
more like a “hot spot analysis” approach. Therefore, it is
unlikely to have a high correlation between parameters
obtained from “whole tumor” and “hot spot” analyses.
However, it was not possible to do co-registered regional
analysis due to the diffuse nature of the optical imaging.
Optical imaging is very sensitive to the depth information,
and tissues near the sensitive region of optical fibers will
have more contribution to the measurement results. For
example, as the case illustrated in Fig. 2, while DCE-MRI
clearly shows a necrotic/cystic core, THC maps shows an
averaged high blood volume, presumably due to the sensi-
tivity to the strongly enhanced tissue near the surface
closer to the source and detector fibers.
DCE-MRI parameters have been shown to be associ-
ated with poor prognostic factors such as high histologic
grade and ER negativity [22]. Nevertheless, there have
been inconsistent results due to different case numbers
and the study population, e.g. Fernández-Guinea et al.
[47]. In our study high Ki-67 expression and triple-
negative breast cancers showed higher Ktrans than their
counterparts with marginal significance, suggesting that
more aggressive tumors have a higher angiogenesis as
measured by DCE-MRI. This result is consistent with a
recent report which showed that the mean Ktrans was
higher in Ki-67-positive tumors than in Ki-67-negative
tumors [48]. For further detailed analysis considering
tumor heterogeneity, a histogram or pixel-by-pixel ana-
lysis can be considered [49]. However, this type of ana-
lysis is not meaningful in US-DOT due to the diffuse
nature of the optical imaging methods.
There were some limitations in this study. First, the
study population was limited to a small number of pa-
tients with malignant tumors who received both US-
DOT and DCE-MRI. Since no benign tumors with lower
angiogenesis were included in the analysis, the dynamic
range was small and less likely to show a good correl-
ation result as published in other studies using a diag-
nostic population. Second, the DCE-MRI was acquired
using a typical clinical protocol with 7 dynamic frames
and 66 s temporal resolution. This coarse temporal reso-
lution was not sufficient to obtain vascular volume char-
acteristics at a very early time after contrast injection,
which is expected to have a better correlation with THC
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measured by US-DOT [50]. Also, we did not measure
the pre-contrast T1 relaxation time T10, and could not
measure the arterial input function from each individual
patient. The T10 and the arterial input function may
vary between patients, and if these parameters can be ac-
curately measured from each patient and used in the
pharmacokinetic model fitting, more precise Ktrans and
kep may be obtained. However, these measurements are
difficult to do and not practical in a clinical setting; also
variations in the resulting Ktrans and kep values are ex-
pected to be small and are not thought to affect the cor-
relation with THC. Nonetheless, the pharmacokinetic
analysis obtained using assumed T10 and the population
blood curves is a common approach and can yield char-
acteristic Ktrans and kep that are highly correlated with
parameters directly calculated from DCE kinetics. The
DCE-MRI was done within 2 weeks after US-DOT. The
vascularity of breast tissues is known to vary in different
phases of a menstrual cycle; therefore, this may intro-
duce a small variation in 16 pre-menopausal women
[51]. However, the vascularity of the tumor is much
higher compared to normal tissues, and it is unlikely to
change much in 2 weeks. Since we were focusing on tu-
mors, the effect of imaging time differences was ex-
pected to be very small.
Conclusions
In conclusion, the pharmacokinetic parameters of DCE-
MRI and total hemoglobin concentration measured by
US-DOT were not well correlated. Although both were
related to tumor angiogenesis, the contrast mechanisms
used by these two modalities were different, and it was
very difficult to match tissues in the analysis particularly
given the heterogeneous nature of breast cancer. Never-
theless, the THC of US-DOT and Ktrans of DCE-MRI
were associated with parameters indicative of tumor ag-
gressiveness with a high angiogenesis in breast cancer.
Currently MRI is recommended for high-risk screening
in Western countries, and it will be very interesting to
see if US-DOT can serve as an alternative imaging mo-
dality with similar diagnostic performance compared to
MRI. More studies are needed to establish the clinical
value of US-DOT.
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